Pharmaceuticals
InnoCare Announces Approval of Clinical Trial of Novel SHP2 Allosteric Inhibitor ICP-189 in China
BEIJING, Oct. 19, 2021 /PRNewswire/ -- InnoCare Pharma (HKEX: 09969) announced today that the Company has received Investigational New Drug (IND) approval from the NMPA for itsSHP2 (Src Homology 2 domain containing protein tyrosine phosphatase) allosteric inhibitor ICP-189, which is the company's...
2021-10-19 12:56
2311
The Journal of Medicinal Chemistry Publishes Study Showing Potential of the Potent EED Inhibitor EEDi-5273 (APG-5918) to Achieve Complete Tumor Regression by Modulating the Epigenetics
SUZHOU, China, and ROCKVILLE, Md., Oct. 18, 2021 /PRNewswire/ -- Ascentage Pharma (6855.HK), a global biopharmaceutical company engaged in developing novel therapies for cancers, chronic hepatitis B (CHB), and age-related diseases, today announced that a research team led by Prof. Shaomeng Wang, ...
2021-10-18 22:42
8031
I-Mab Announces IND Approval for Phase 2 Clinical Trial of Efineptakin Alfa in Combination with PD-1 Therapy in China
SHANGHAI and GAITHERSBURG, Md., Oct. 18, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel biologics, today announced that the Center for Drug Evaluation (CDE) of the China ...
2021-10-18 20:00
2101
Akeso is Rapidly Advancing The Phase II Clinical Trial of IL-4R Monoclonal Antibody (AK120) for the Treatment of Atopic Dermatitis and Asthma
HONG KONG, Oct. 15, 2021 /PRNewswire/ -- Akeso, Inc. (the Company, 9926.HK) announces that the Company's self-developed innovative drug candidate, IL-4R monoclonal antibody (AK120), was approved by the Center for Drug Evaluation (CDE) of the National Medical Products Administration ofthe People...
2021-10-15 12:44
2365
I-Mab Advances Late-stage Development of Its Differentiated CD38 Antibody Felzartamab (TJ202) in China
* Completed patient enrollment in phase 3 registrational trial of felzartamab in combination with lenalidomide for second-line treatment of multiple myeloma (MM) * Felzartamab for MM third-line treatment is on track for BLA submission in Q4 2021 * New IND application for combination of felz...
2021-10-13 20:00
1855
Shanghai, industry partners to co-build world-class biopharma industry cluster
SHANGHAI, Oct. 13, 2021 /PRNewswire/ -- This is a report from China.org.cn: The 2021 International Biopharma Industry Week opened in Shanghai on Oct. 11, bringing together industry gurus, research minds, investors, and government representatives to discuss the latest trends in the biopharmaceutic...
2021-10-13 19:43
1894
The CDE Approved IND Application to Investigate Combination of Asieris' APL-1202 and BeiGene's Tislelizumab as Neoadjuvant Therapy for MIBC Patients
SHANGHAI, Oct. 13, 2021 /PRNewswire/ -- Asieris Pharmaceuticals (Asieris) today announced that the Center for Drug Evaluation (CDE) NMPA has approved the Investigational New Drug (IND) application of oral APL-1202 in combination with BeiGene's tislelizumab as neoadjuvant therapy in patients with ...
2021-10-13 15:47
1677
Accelerate Innovation Towards the Future，SAB of Winhealth Pharma Formally Established
HANGZHOU, China, Oct. 12, 2021 /PRNewswire/ -- On October 12, 2021, Hong Kong Winhealth Pharma Group, (hereinafter referred to as "Winhealth Pharma") announced the formal establishment of its Scientific Advisory Board (SAB), aiming to further expand and optimize the Group's strategic layout in m...
2021-10-12 23:45
3244
CBC-backed Jadeite Medicines Announces Exclusive Licensing Agreement with Albireo Pharma to Develop and Promote Odevixibat in Japan
TOKYO, Oct. 12, 2021 /PRNewswire/ -- Jadeite Medicines Inc. ("Jadeite"), a biopharmaceutical company that is backed bySingapore's CBC Group ("CBC") and committed to addressing critical unmet medical needs for patients inJapan, today entered into an exclusive licensing agreement with Albireo Pharm...
2021-10-12 20:30
1665
Shanghai Pharmaceuticals and Luca Healthcare Announce a Strategic Collaboration to Provide Home Drug Delivery to Rare Disease Patients on Luca Healthcare's Patient Management Platform
SHANGHAI, Oct. 12, 2021 /PRNewswire/ -- SPH Health Commerce, the Direct-to-Patient ("DTP") retail pharmacy subsidiary of Shanghai Pharmaceuticals and Luca Healthcare,China's category leader in clinically validated, software-based screening, treatment and management tools, today announced a strat...
2021-10-12 19:21
2924
Kintor Pharma Announces China NMPA Approves Clinical Trial of ALK-1 and Nivolumab Combination Therapy for the First-line Treatment of Advanced Hepatocellular Carcinoma
SUZHOU, China, Oct. 11, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that the clinical trial of ALK-1 antibody (GT90001C) and Nivolumab (O...
2021-10-11 13:00
6634
Winhealth-CARD Cooperation Boosts Rare Disease Healthy Ecosystem Construction
BOAO, China, Oct. 8, 2021 /PRNewswire/ -- On September 30, 2021 (Hainan-Bo'ao), Hongkong Winhealth Pharma Group (Winhealth Pharma) and the China Alliance for Rare Disease (CARD) officially signed a five-year strategic collaboration agreement. The cooperation involved rare disease registration and...
2021-10-08 23:01
4205
Kazia Therapeutics to Present at LD Micro Main Event
SYDNEY, Oct. 6, 2021 /PRNewswire/ -- Kazia Therapeutics Limited (NASDAQ: KZIA; ASX: KZA), an oncology-focused drug development company, is pleased to announce that CEO, DrJames Garner, will be presenting at the LD Micro Main Event, to be held virtually and in person from12-14 October 2021. Since...
2021-10-06 22:00
8558
I-Mab and ABL Bio to Present Preclinical Data of TJ-CD4B/ABL111 and TJ-L14B/ABL503 at the 2021 SITC Annual Meeting
SHANGHAI and GAITHERSBURG, Md., Oct. 5, 2021 /PRNewswire/ -- I-Mab (Nasdaq: IMAB), a clinical-stage biopharmaceutical company committed to the discovery, development, and commercialization of novel or highly differentiated biologics, and ABL Bio, Inc. (Kosdaq:298380, hereafter "ABL"), a South Kor...
2021-10-05 20:00
9633
Pharmaxis Cleared To Progress To Phase 2 Bone Marrow Cancer Trial
SYDNEY, Oct. 5, 2021 /PRNewswire/ -- Clinical stage drug development company Pharmaxis Ltd (ASX: PXS) today announced further positive results of data analysis from a phase 1c clinical trial (MF-101) studying its drug PXS-5505 in patients with the bone marrow cancer myelofibrosis for 28 days at t...
2021-10-05 18:00
2233
Kintor Pharma Announces First Patient Dosing in Phase III Clinical Trial of Proxalutamide for the Treatment of Hospitalized COVID-19 Patients in US
SUZHOU, China, Oct. 4, 2021 /PRNewswire/ -- Kintor Pharmaceutical Limited ("Kintor Pharma", HKEX: 9939), a clinical-stage biotechnology company developing innovative small molecule and biological therapeutics, announced today that onOctober 1 its phase III clinical trial of proxalutamide for the ...
2021-10-04 16:30
10440
I-Mab Announces Upcoming Participation at October Conferences
SHANGHAI and GAITHERSBURG, Md., Oct. 1, 2021 /PRNewswire/ -- I-Mab (the "Company") (Nasdaq: IMAB), a clinical stage biopharmaceutical company committed to the discovery, development and commercialization of novel biologics, today announced its participation in the following conferences in October...
2021-10-01 20:00
14850
Binhai sets ambitious biomedical goals with support of key companies
TIANJIN, China, Sept. 30, 2021 /PRNewswire/ -- A news report by chinadaily.com.cn: The Binhai New Area in North China's port city of Tianjin has gathered together more than 1,500 biomedical companies that have made great scientific achievements in key areas, such as recombinant proteins and stem...
2021-10-01 01:08
1957
Penn mRNA Biology Pioneer Drew Weissman Joins RVAC's Science Advisory Board
SINGAPORE, Sept. 30, 2021 /PRNewswire/ -- RVAC Medicines Pte. Ltd. ("RVAC"), an emerging messager RNA (mRNA) platform company inSingapore aspiring to address various diseases with unmet medical needs for emerging markets through novel vaccines and therapeutics, today announced that one of the to...
2021-10-01 00:50
2500
Clarity and Evergreen enter Targeted Copper Theranostics manufacturing agreement for US Clinical trials
SYDNEY, Sept. 30, 2021 /PRNewswire/ -- Clarity Pharmaceuticals (ASX: CU6) ("Clarity"), an Australian-based clinical stage radiopharmaceutical company developing next-generation products to address the growing need in oncology, and Evergreen Theragnostics, Inc. ("Evergreen"), a radiopharmaceutical...
2021-09-30 20:03
1948
Week's Top Stories
Most Reposted
Visa and Trip.com Group Ink Strategic Collaboration, Enabling Consumers to Chase Their Passions Through Travel
[Picked up by 309 media titles]
2026-05-19 18:10
Two-day Global Prosperity Summit 2026 officially opens
[Picked up by 308 media titles]
2026-05-19 23:59
Two‑day Global Prosperity Summit 2026 concludes successfully
[Picked up by 303 media titles]
2026-05-21 22:13
Hyundai Motor Group to Pioneer Hong Kong's Hydrogen Economy, Accelerating Asia-Pacific Expansion
[Picked up by 290 media titles]
2026-05-18 15:30
Autonomous AI marketing platform Protaigé launches with Maia, the world's first AI Account Director that operates within the flow of work
[Picked up by 281 media titles]
2026-05-20 09:15Most Read
NYSE Content Update: Lincoln International Pops by 13% in First Day of Trade
2026-05-21 21:04
6824
Scienjoy Holding Corporation Reports Unaudited First Quarter 2026 Financial Results
2026-05-21 20:30
6752
/C O R R E C T I O N -- The American Chamber of Commerce in Singapore (AmChamSG)/
2026-05-21 12:14
6269
NYSE Content Update: Armada Raises $230 Million, Boosts Valuation to $2 Billion
2026-05-19 21:02
6202
